Issued: 21 February 2025, London UK
GSK announces Dr Gavin Screaton to join the Board as Non-Executive Director
Dr Jesse Goodman to retire after 9 years of service
GSK plc (LSE/NYSE: GSK) has today announced that Dr Gavin Screaton will join the Board of the Company as a Non-Executive Director from 1 May 2025. Dr Screaton's appointment follows a search to replace the skills and experience of Dr Jesse Goodman who steps down from the Board after the company's Annual General Meeting in May 2025, after nine years of service.
Dr Screaton is currently Head of the world-leading1 Medical Sciences Division at the University of Oxford, and an expert in the field of immunology and infectious diseases, two areas of science critical to GSK.
Dr Screaton is a Fellow of the Academy of Medical Sciences, a Fellow of the Royal College of Physicians, and a former Senior Investigator at the National Institute for Health Research in the United Kingdom. He is also a Non-Executive Director of Oxford University Hospitals NHS Foundation Trust and a Trustee of the Jenner Vaccine Foundation. He also co-founded RQ Bio, a biotech company focused on development of preventative medicines to provide immunity and protection against viral infectious diseases.
On appointment, Dr Screaton will become a member of the GSK Board Science Committee and the Corporate Responsibility Committee.
Sir Jonathan Symonds, Chair of GSK said, "We are delighted to welcome Gavin to the Board of GSK. His deep expertise in immunology and infectious diseases, which are core areas of scientific research focus for GSK, together with his considerable experience in public health, will bring valuable perspective to the Board.
The appointment will also help to replace the skillset and experience of Jesse Goodman who steps down from the GSK Board after nine years of service. As a former FDA Chief Scientist, the Board as a whole and the Science Committee in particular, has benefitted hugely from Jesse's wealth of expertise in infectious diseases, regulation and public health. He has made a fantastic contribution to GSK and we wish Jesse all the very best for the future."
_________________________
1The University of Oxford is ranked first in Times Higher Education (THE) World University Rankings for Medicine, as of January 2025. This is the 14th consecutive year that Oxford has led the THE subject rankings in medicine.
Notes:
| | 1. The appointment of Dr Screaton was made by the Board on the recommendation of the Nominations & Corporate Governance Committee. The Committee conducted an extensive search and selection process for this appointment, using an external search firm, which is a signatory of the Voluntary Code of Conduct for Executive Search Firms. The external search firm provided a comprehensive list of candidates who were approached, evaluated and interviewed against an agreed set of criteria aligned to the Board's target skills matrix. The Board satisfied itself that Dr Screaton had the experience and time available to carry out the role.
| ||||||||||||||||||||||||||
| | 2. The Board has determined that Dr Screaton is an independent Non-Executive Director in accordance with the UK Corporate Governance Code.
| ||||||||||||||||||||||||||
| | 3. Dr Screaton will receive the standard basic fee for a Non-Executive Director of £122,258 per annum (including travel allowance). He will also receive fees of £30,000 per annum as a scientific and medical expert. Dr Screaton will be required to build towards a share ownership requirement of GSK shares in accordance with the Company's shareholder approved Non-Executive remuneration policy.
| ||||||||||||||||||||||||||
| | 4. "Scientific and Medical Expert" - The Board designates Non-Executive Directors whose expertise or backgrounds as renowned medical scientists, researchers, or physicians mean that they can bring scientific or industry expertise to the Board's deliberations.
| ||||||||||||||||||||||||||
| | 5. Dr Screaton does not have a service contract. He has a letter of appointment which may be viewed by contacting the Company Secretary at the Company's registered office.
| ||||||||||||||||||||||||||
| | 6. There are no further disclosures to be made in respect of Dr Screaton's appointment under Listing Rule 6.4.8R
| ||||||||||||||||||||||||||
| | 7. As of 1 May 2025, the Board of GSK will comprise:
|
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
| GSK enquiries | | | |
| Media: | Tim Foley | +44 (0) 20 8047 5502 | (London) |
| | Kathleen Quinn | +1 202 603 5003 | (Washington DC) |
| | |
| |
| Investor Relations: | Annabel Brownrigg-Gleeson | +44 (0) 7901 101944 | (London) |
| | James Dodwell | +44 (0) 20 8047 2406 | (London) |
| | Mick Readey | +44 (0) 7990 339653 | (London) |
| | Camilla Campbell | +44 (0) 7803 050238 | (London) |
| | Steph Mountifield | +44 (0) 7796 707505 | (London) |
| | Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) |
| | Frannie DeFranco | +1 215 751 4855 | (Philadelphia) |
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and GSK's Q4 Results for 2024.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.